BPOM: Developing Biosimilar Products Will Strengthen National Manufacturing
Jakarta (ANTARA) – The National Agency of Drug and Food Control (BPOM) said stronger development of biosimilar products, through investment, regulation and increased scientific capacity, is important to improving Indonesia’s ability to manufacture biological products.
BPOM head Taruna Ikrar said in Jakarta on Wednesday that biosimilars are biological products highly similar to a reference biological product, but not identical. He said confidence in biosimilars must be built through guarantees of safety, efficacy and quality supported by scientific evidence.
He explained that Indonesia’s biosimilar development ecosystem is currently supported by seven biosimilar industries and 159 clinical trial sites. This potential needs to be strengthened through sustained investment, greater scientific capacity, regulatory assistance and alignment of standards with international requirements.
“Biosimilar evaluation therefore requires a comprehensive approach covering analytical characterisation, functional testing, pharmacokinetics and pharmacodynamics, immunogenicity, and clinical data as needed to demonstrate product comparability,” Taruna said.
In evaluating biosimilar products, BPOM applies a ‘totality of evidence’ approach, drawing on international guidelines and applicable regulations.
Using a scientific evidence-based approach, BPOM ensures that product registration decisions are based on compliance with safety, efficacy and quality requirements, rather than on general product similarity alone.
“BPOM currently provides expedited evaluation pathways, with a 50-working-day timeframe for the development of new medicines and investment in Indonesia, 90 working days through the reliance mechanism, and 100 working days for certain medicine categories in accordance with applicable rules,” he said.
Regulatory oversight does not end when a product receives marketing authorisation. Post-market safety and quality monitoring remains necessary to identify potential risks and maintain public confidence in biosimilars.
He said national biosimilar development also requires sustained collaboration, including through an Academia–Business–Government (ABG) approach. Academics help drive innovation and strengthen research capacity; industry is responsible for developing products and ensuring consistent quality; and the government ensures regulatory compliance and protects public health.
“Every permit and approval I sign at BPOM is a step towards protecting human life,” Taruna said. His statement underscored that strengthening the biosimilar industry and accelerating access to medicines must remain grounded in protecting public health.
Similarly, Rachmat Kaimuddin, managing director for development investment at Danantara Development Management Fund (DDMF), emphasised the importance of adapting plans for the development of the national biosimilar industry.
He said several areas require attention, from the selection of raw materials and supervision of production processes to financial management. He also said stronger oversight is important to support orderly and controlled production.
Meanwhile, Carina Citra Dewi Joe, honorary professor at Airlangga University, stressed the importance of working with BPOM to build a trusted system of quality and standardisation. These standards need to be applied throughout the value chain, from upstream to downstream, including production processes and the quality of the resulting products, to support the development of high-quality biosimilars.
“In supporting the development of the biological industry, the implementation of Good Manufacturing Practices (CPOB) is important to ensure consistent product quality from one batch to the next. Industry must ensure validation of production processes, contamination control and the implementation of an adequate quality system,” she said.
Source: jawawa.id (https://jawawa.id/newsitem/bpom-developing-biosimilar-products-will-strengthen-national-manufacturing-1793768059)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5830691/bpom-pengembangan-produk-biosimilar-kuatkan-manufaktur-nasional), translated from Indonesian